Summary of indirect comparisons to evaluate efficacy of baricitinib with targeted synthetic and biologic disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis

被引：0

作者：

Emery, P. ^{[1
]}

Dudler , J. ^{[2
]}

Smolen, J. ^{[3
]}

Zerbini, C. ^{[4
]}

Burmester, G. ^{[5
]}

Fautrel, B. ^{[6
]}

van de Laar, M. ^{[7
]}

Fleischmann, R. ^{[8
]}

Fakhouri, W. ^{[9
]}

De Leonardis, F. ^{[9
]}

Zhu, B. ^{[9
]}

Kadziola, Z. ^{[9
]}

De La Torre, I ^{[9
]}

Perrier, C. ^{[9
]}

Taylor, P. ^{[10
]}

机构：

[1] Leeds MSK Biomed Chapel Allerton Hosp, Leeds, W Yorkshire, England

[2] HFR Fribourg Hop Cantonal, Fribourg, Switzerland

[3] Med Univ Vienna, Vienna, Austria

[4] Ctr Paulista Invest Sao Paulo Clin, Sao Paulo, Brazil

[5] Charite Univ Med Berlin, Dept Rheumatol & Clin Immunol, Berlin, Germany

[6] Pierre & Marie Curie, Paris, France

[7] Arthritis Ctr Twente, Enschede, Netherlands

[8] Univ Texas SouthWestern Med Ctr, Dallas, TX USA

[9] Eli Lilly & Co, Indianapolis, IN USA

[10] Univ Oxford, Botnar Res, Headington, England

来源：

SWISS MEDICAL WEEKLY | 2019年

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

P 6

引用

页码：7S / 8S

页数：2

共 50 条

[21] Differences in trajectory of disease activity according to biologic and targeted synthetic disease-modifying anti-rheumatic drug treatment in patients with rheumatoid arthritis
Bon San Koo
Seongho Eun
Kichul Shin
Seokchan Hong
Yong-Gil Kim
Chang-Keun Lee
Bin Yoo
Ji Seon Oh
Arthritis Research & Therapy, 24
[22] Differences in trajectory of disease activity according to biologic and targeted synthetic disease-modifying anti-rheumatic drug treatment in patients with rheumatoid arthritis
San Koo, Bon
Eun, Seongho
Shin, Kichul
Hong, Seokchan
Kim, Yong-Gil
Lee, Chang-Keun
Yoo, Bin
Oh, Ji Seon
ARTHRITIS RESEARCH & THERAPY, 2022, 24 (01)
[23] The economic burden of switching targeted disease-modifying anti-rheumatic drugs among rheumatoid arthritis patients
Shahabi, Ahva
Shafrin, Jason
Zhao, Lauren
Green, Sarah
Curtice, Tammy
Marshall, Alexander
Paul, Damemarie
JOURNAL OF MEDICAL ECONOMICS, 2019, 22 (04) : 350 - 358
[24] Use of biologic or targeted-synthetic disease-modifying anti-rheumatic drugs and risk of diabetes treatment intensification in patients with rheumatoid arthritis and diabetes mellitus
Chen, Sarah K.
Lee, Hemin
Jin, Yinzhu
Liu, Jun
Kim, Seoyoung C.
RHEUMATOLOGY ADVANCES IN PRACTICE, 2020, 4 (02) : 1 - 11
[25] Decreased chronic kidney disease in rheumatoid arthritis in the era of biologic disease-modifying anti-rheumatic drugs
Hanaoka, Hironari
Kikuchi, Jun
Hiramoto, Kazuoto
Saito, Shuntaro
Kondo, Yasushi
Kaneko, Yuko
CLINICAL KIDNEY JOURNAL, 2022, 15 (07) : 1373 - 1378
[26] SARCOPENIA IN PATIENTS WITH RHEUMATOID ARTHRITIS ON THE TREATMENT WITH BIOLOGIC DISEASE MODIFYING ANTI-RHEUMATIC DRUGS
Hasegawa, E.
Ito, S.
Kurosawa, Y.
Taniguchi, S.
Kobayashi, D.
Abe, A.
Otani, H.
Nakazono, K.
Murasawa, A.
Narita, I.
Ishikawa, H.
ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 985 - 985
[27] Assessment of adherence to disease-modifying anti-rheumatic drugs in rheumatoid arthritis
Monchablon, Clelia
Gonde, Henri
Pouplin, Sophie
Varin, Remi
Vittecoq, Olivier
Lequerre, Thierry
CLINICAL RHEUMATOLOGY, 2020, 39 (01) : 207 - 216
[28] Disease-modifying anti-rheumatic drugs in rheumatoid arthritis and ankylosing spondylitis
Haibel, H.
Specker, C.
CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2009, 27 (04) : S159 - S163
[29] ADHERENCE TO BIOLOGIC AND CONVENTIONAL DISEASE MODIFYING ANTI-RHEUMATIC DRUGS IN PATIENTS WITH RHEUMATOID ARTHRITIS
Mishra, P.
VALUE IN HEALTH, 2018, 21 : S198 - S198
[30] Effect of biologic disease-modifying anti-rheumatic drugs for patients with rheumatoid arthritis who hope to become mothers
Shimada, Hiromi
Kameda, Tomohiro
Kanenishi, Kenji
Miyatake, Nobuyuki
Nakashima, Shusaku
Wakiya, Risa
Kato, Mikiya
Miyagi, Taichi
Mansour, Mai Mahmoud Fahmy
Hata, Toshiyuki
Kadowaki, Norimitsu
Dobashi, Hiroaki
CLINICAL RHEUMATOLOGY, 2019, 38 (05) : 1453 - 1458

← 1 2 3 4 5 →